Research Study

An Observer-blind Study to Evaluate the Efficacy, Safety, Reactogenicity and Immunogenicity of the GSK Biologicals' Investigational Vaccine GSK3277511A When Administered to COPD Patients
Principal Investigator 
Mark FitzGerald

Overview

Body Locations and Systems 
COPD
ClinicalTrials.gov# 
NCT03281876
Status 
Closed for Recruitment
Study Start/End 
Feb 5, 2018 to Feb 24, 2020
Locations 
Diamond Health Care Centre
Name/Title 
Shelley Abercromby, Research Coordinator
Phone 
604-875-4111 ext.62500
Purpose of Study 

The purpose of this study is to test if the vaccine is working well in COPD patients aged 40 to 80 years old to reduce episodes of worsening symptoms ("exacerbations") and to gather further information on safety and immune response.

Eligibility 

Visit ClinicalTrials.gov for more information.

Disclaimer 

Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific research studies only. If you have specific questions which require clinical expertise, please call your primary care physician.